PMID- 24997081
OWN - NLM
STAT- MEDLINE
DCOM- 20140919
LR  - 20181202
IS  - 1790-5427 (Print)
IS  - 1790-5427 (Linking)
VI  - 17
IP  - 2
DP  - 2014 May-Aug
TI  - Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose 
      PET/CT better assess response after 3-weeks treatment by epidermal growth factor 
      receptor kinase inhibitor, in non-small lung cancer patients? Preliminary 
      results.
PG  - 90-6
LID - 10.1967/s002449910136 [doi]
AB  - The objectives of this study was to study the diagnostic efficacy of 
      3'-deoxy-3'-fluorine-18-fluorothymidine ((18)F-FLT) and of 
      2'-deoxy-2'-(18)F-fluoro-d-glucose ((18)F-FDG) positron emission 
      tomography/computed tomography (PET/CT) for response evaluation following three 
      weeks treatment by epidermal growth factor receptor-tyrosine kinase inhibitor 
      (EGFR-TKI) in non small cell lung cancer (NSCLC) patients. Fifteen patients of 
      advanced stage (IIIB-IV) NSCLC planned for oral 1st or 2nd/3rd line EGFR-TKI 
      treatment were enrolled in the study. Baseline, prior to treatment, and follow-up 
      after three weeks, (18)F-FLT and (18)F-FDG PET/CT imaging was performed in all 
      patients. The standard uptake lean body mass (SULpeak) and total lesion 
      glycolysis (TLG) values of the hottest lesions were calculated in all patients 
      using semi-quantitative analysis. Statistical analysis on PET semi-quantitative 
      data was used to evaluate the overall survival (OS) and progression free survival 
      (PFS). The patients were either classified as responders or non-responders or at 
      a steady state according to the PET response criteria in solid tumors (PERCIST). 
      The receiver operating characteristic curve (ROC) analysis was done on the 
      (18)F-FDG PET/CT clinical responders, to derive the cut-off values on the 
      corresponding data sets between responders and non responders. Results showed 
      that in responders (18)F-FDG SULpeak values better predicted OS and PFS values 
      when compared to (18)F-FLT SULpeak values and also were a better predictor of OS 
      as compared to the TLG values. In responders, the ROC analysis carried out on 
      (18)F-FLT PET/CT imaging data in responders indicated a decrease of >/=22% in 
      SULpeak and a decrease of >/=0.7 in absolute values. Three (3/15) patients 
      developed resistance to EGFR-TKI treatment at 3 months of follow-up. In 
      conclusion, in both responders and in non responders, patients with NSCLC treated 
      for 3 weeks by EGFR-TKI, both OS and PFS were better predicted by (18)F -FDG 
      SULpeak than by (18)F -FLT SULpeak. Although, the difference was only borderline, 
      yet, (18)F -FDG SULpeak was a better predictor of OS compared to TLG values. 
      However, to validate these findings, studies need to be carried in a larger 
      number of patients.
FAU - Bhoil, Amit
AU  - Bhoil A
AD  - Department of Nuclear Medicine and PET, PGIMER, Chandigarh-160012, India. 
      drbsingh5144@yahoo.com.
FAU - Singh, Baljinder
AU  - Singh B
FAU - Singh, Navneet
AU  - Singh N
FAU - Kashyap, Raghava
AU  - Kashyap R
FAU - Watts, Ankit
AU  - Watts A
FAU - Sarika, Sharma
AU  - Sarika S
FAU - Mittal, Bhagwant Rai
AU  - Mittal BR
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20140705
PL  - Greece
TA  - Hell J Nucl Med
JT  - Hellenic journal of nuclear medicine
JID - 101257471
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PG53R0DWDQ (alovudine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*diagnosis/diagnostic imaging/drug therapy
MH  - *Dideoxynucleosides
MH  - Disease-Free Survival
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Lung Neoplasms/*diagnosis/diagnostic imaging/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging
MH  - *Positron-Emission Tomography
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Time Factors
MH  - *Tomography, X-Ray Computed
MH  - Treatment Outcome
EDAT- 2014/07/06 06:00
MHDA- 2014/09/23 06:00
CRDT- 2014/07/06 06:00
PHST- 2014/04/01 00:00 [received]
PHST- 2014/06/23 00:00 [accepted]
PHST- 2014/07/06 06:00 [entrez]
PHST- 2014/07/06 06:00 [pubmed]
PHST- 2014/09/23 06:00 [medline]
AID - s002449910136 [pii]
AID - 10.1967/s002449910136 [doi]
PST - ppublish
SO  - Hell J Nucl Med. 2014 May-Aug;17(2):90-6. doi: 10.1967/s002449910136. Epub 2014 
      Jul 5.